Evidence map›Paper›PMID 28557342›Full record

ArticleCancer medicine2017

Morphologic characterization of residual DNA methylation in the gastric mucosa after Helicobacter pylori eradication.

Sayumi Tahara, Tomomitsu Tahara, Tetsuya Tuskamoto, Noriyuki Horiguchi, Tomohiko Kawamura, Masaaki Okubo, Takamitsu Ishizuka, Mitsuo Nagasaka, Yoshihito Nakagawa, Tomoyuki Shibata and 2 more

Abstract read
In one paragraph

Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Epigenetic alterations inJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Review
  5. Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sayumi TaharaDepartment of Diagnostic Pathology I, Fujita Health University School of Medicine, Toyoake, Japan.ORCID http://orcid.org/0000-0002-1901-5056
Tomomitsu TaharaDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Tetsuya TuskamotoDepartment of Diagnostic Pathology I, Fujita Health University School of Medicine, Toyoake, Japan.
Noriyuki HoriguchiDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Tomohiko KawamuraDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Masaaki OkuboDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Takamitsu IshizukaDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Mitsuo NagasakaDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshihito NakagawaDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Tomoyuki ShibataDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
Makoto KurodaDepartment of Diagnostic Pathology I, Fujita Health University School of Medicine, Toyoake, Japan.
Naoki OhmiyaDepartment of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Residual DNA methylation in the gastric mucosa after Helicobacter pylori (H. pylori) eradication may have a role in gastric carcinogenesis. We examined the association between morphologic features and promoter methylation status of non-neoplastic gastric mucosa especially after H. pylori eradication. A total of 140 gastric specimens from 99 participants who had at least 6 months of post-eradication period were examined. The magnifying narrow-band imaging (NBI) endoscopic feature of gastric mucosa was divided into two types: restored-small, round pits, accompanied with honeycomb-like subepithelial capillary networks; atrophic-well-demarcated oval or tubulovillous pits with clearly visible coiled or wavy vessels. Methylation status of five candidate genes (MYOD1, SLC16A12, IGF2, RORA, and PRDM5) were examined by bisulfite pyrosequencing. The atrophic type, informative endoscopic features of intestinal metaplasia, demonstrated higher methylation levels in all five genes compared to the restored type (all P < 0.0001). In the restored type, methylation levels were significantly lower among the samples with longer post-eradication period (for all genes, P < 0.0001), which was not observed in atrophic type (for all genes, P > 0.1). Multivariate analysis demonstrated that atrophic type or presence of intestinal held an independent factor for hyper methylation (odds ratio: 24.69, 95% confidence interval: 6.95-87.76, P < 0.0001). The atrophic type by the magnifying NBI and presence of intestinal metaplasia are the morphologic characteristics of residual DNA methylation of after H. pylori eradication, regardless of the post-eradication period and it might be considered as the epigenetic irreversible point with H. pylori eradication.

Indexed as

DNA MethylationAdultAgedAged, 80 and overAnti-Bacterial AgentsCell Transformation, NeoplasticEndoscopy, GastrointestinalGastric MucosaGene Expression RegulationHelicobacter InfectionsHelicobacter pyloriHumansMiddle AgedOdds RatioPromoter Regions, GeneticRisk FactorsAnti-Bacterial AgentsDNA methylationgastric mucosaH. pylori eradicationnarrow-band imaging endoscopy

Identifiers

PMID28557342
PMCPMC5504328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.